A novel mechanism by which iron overload in the tumor microenvironment triggers ferroptosis in CD8⁺ T cells | Guangzhou National Laboratory publishes in Nature Communications, revealing a key pathway of immune evasion (IF: 18.2)
Release Date:
2026-08-06 21:41
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published in the internationally renowned academic journal “...” Nature Communications published a research paper titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction.” This study is the first to systematically demonstrate that iron overload in the tumor microenvironment suppresses iron efflux proteins. SLC40A1 It elucidates the core mechanisms underlying CD8⁺ T-cell ferroptosis and functional exhaustion, and innovatively proposes a novel strategy: genetically engineering CAR‑T cells to overexpress SLC40A1, thereby conferring resistance to tumor‑induced iron stress. This approach offers significant theoretical advances and an engineered solution for the immunotherapy of solid tumors.
Paper Information
- Title: Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction
- Title: A Novel Mechanism by Which Iron Overload in the Tumor Microenvironment Triggers Ferroptosis in CD8⁺ T Cells
- Journal: Nature Communications
- Impact Factor: 18.2
- Affiliation: Guangzhou National Laboratory, The Third Affiliated Hospital of Sun Yat-sen University
- First author: Lin Zhenyu
- Corresponding author: Bian Yingjie
- Publication Date: May 22, 2026
- DOI: 10.1038/s41467-026-73379-4
Research Background
The regulation of iron homeostasis in tumor cells is well established, yet its immunomodulatory effects on CD8⁺ T cells within the tumor microenvironment remain poorly understood. Clinical data indicate that cancer patients often exhibit systemic iron deficiency, but it remains unclear whether the local tumor microenvironment also suffers from iron depletion. Ferroptosis, a form of iron‑dependent cell death driven by lipid peroxidation, plays a particularly salient role in tumor immune evasion and warrants close scrutiny. However, whether tumors suppress antitumor immunity by inducing ferroptosis in CD8⁺ T cells has, until now, lacked direct evidence.
Research Content
The research team analyzed tumor tissues, peripheral blood, lymphatic fluid, and tumors from patients with colorectal cancer and lung cancer, as well as from various tumor-bearing mouse models. Interstitial fluid Multi-omics analyses were conducted, revealing for the first time:
Iron Overload in the Tumor Microenvironment: Despite iron deficiency in patients’ peripheral blood, iron concentrations are markedly elevated in tumor interstitial fluid and malignant pleural and peritoneal effusions, primarily resulting from iron release from areas of tumor necrosis.
Ferroptosis in CD8⁺ T cells is positively correlated with exhaustion: tumor-infiltrating CD8⁺ T cells exhibit marked iron accumulation, and iron levels are positively associated with the PD-1⁺TIM-3⁺ exhaustion phenotype and cell death.
SLC40A1 is a critical regulatory node: chronic TCR stimulation suppresses SLC40A1 transcription and translation, while tumor-derived hepcidin further promotes SLC40A1 degradation, leading to impaired iron efflux in CD8⁺ T cells, intracellular iron overload, and ferroptosis.
Gene repair and pharmacological intervention strategies: overexpression of SLC40A1 or the use of… Iron chelator Deferoxamine can significantly reverse CD8⁺ T-cell dysfunction and inhibit tumor growth.
Engineered CAR-T cells: By constructing CAR-T cells that overexpress SLC40A1, researchers have successfully countered ferroptosis induced by iron overload in the tumor microenvironment, demonstrating enhanced infiltration and antitumor efficacy across multiple solid tumor models.
Research Innovation Points
Disruptive Clinical Discovery
For the first time, it has been demonstrated in clinical samples that, despite systemic iron deficiency in cancer patients, the tumor microenvironment exhibits marked iron overload and directly induces ferroptosis in CD8⁺ T cells.
Multi-level Mechanism Analysis
It comprehensively elucidates the molecular pathways through which SLC40A1 is suppressed at the transcriptional, translational, and protein degradation levels, revealing a novel mechanism of synergistic crosstalk between chronic TCR signaling and tumor-derived hepcidin.
Interpretation of Differential Sensitivity
By comparing the differential sensitivity of CD8⁺ T cells and tumor cells to ferroptosis, we found that CD8⁺ T cells are more susceptible to damage due to their low expression of protective genes such as GPX4 and FSP1, thereby explaining why tumors can evade ferroptosis while immune cells undergo ferroptotic cell death.
Original Engineering Transformation Strategy
For the first time, SLC40A1 overexpression has been incorporated into CAR‑T cell engineering, fundamentally reprogramming cellular iron homeostasis to enable active adaptation to the tumor‑induced iron‑toxic microenvironment—outperforming conventional pharmacological protection strategies.
Significance and Prospects of the Study
This study not only unveils, from a novel perspective, the critical mechanisms by which tumors evade immune surveillance via the “iron overload–ferroptosis” axis, but also offers a precise solution to the “persistence dilemma” in CAR‑T cell therapy for solid tumors. SLC40A1‑overexpressing CAR‑T cells simultaneously possess dual advantages—resistance to ferroptosis and potent cytotoxicity—making them a promising cornerstone for next‑generation CAR‑T therapies targeting solid malignancies. Moreover, patients’ baseline iron metabolism status may serve as a novel biomarker for predicting the efficacy of immunotherapy, providing valuable guidance for the development of personalized treatment strategies.
Shanghai Hycells Biotechnology Co., Ltd. provided fresh apheresis blood and PBMC isolation services for this cutting-edge research. Serving as the starting point and cornerstone of CAR‑T cell manufacturing, both fresh and cryopreserved Leukopak (apheresis‑derived products) and peripheral blood mononuclear cells (PBMCs) sourced from healthy donors or patients are subjected to standardized processing and precise cryopreservation, thereby establishing a robust foundation for downstream experimentation and production.
Hycells’s T-cell culture product portfolio comprehensively covers key steps including apheresis processing, magnetic bead‑based cell sorting, cell activation and expansion, and cryopreservation. Its core offerings include fresh apheresis blood, the HiMag™ sorting kit, and HiXpan. ® Platelet lysate and T‑cell activation kits offer a systematic solution that precisely meets the stringent demands of today’s high‑impact research for experimental system stability and reproducibility. As an innovative biotechnology company with a long-standing focus on the development of primary cell technologies and services, Heyou Bio leverages a robust primary cell resource bank and a high‑quality suite of culture and cryopreservation reagents to provide a solid foundation for constructing complex cellular models and validating their functions, thereby continuously supporting both basic research and the translation of scientific findings into practical applications.
Comprehensive T-cell Culture Solutions · Integrated Product Portfolio
Item number | Product Name |
hPBLP001 | Fresh hPB Leukopak Separate Service, 1000 million |
hPB3T-10C-NS | Frozen hPB T cells Separate Service (NS), 10 million |
MNC-h3NS100 | HiMag TM Human CD3 Negative Isolation Kit |
MNC-h4PS100 | HiMag TM Human CD4 Positive Isolation Kit |
MNC-h8PS100 | HiMag TM Human CD8 Positive Isolation Kit |
HYS01002-kit | Human T-Activator kit (4×10 7 cells) |
HYS01016 | HiXpan® Cell Culture Supplement (Human Platelet Lysate) |
HYS-CF1000 | Cell Feeder Bottom-Permeable Cell Culture Flask |
HYS01013 | Serum-Free Cell Freezing Medium |
- T-cell sample resources
As the starting material and foundational core of the entire CAR‑T cell manufacturing process, fresh or cryopreserved Leukopak (apheresis‑derived blood products) undergo standardized processing and are securely cryopreserved, laying a robust foundation for downstream experimentation and production. Peripheral blood mononuclear cells (PBMCs) derived from healthy donors or patients, along with highly purified, sorted T cells, constitute the essential material basis that drives the seamless progression of in vitro research, process development, and validation studies, providing reliable support at every stage.
- T Cell Sorting Kit
Using the HiMag™ magnetic bead‑based sorting kit, highly pure CD8⁺ T cells can be positively selected from PBMCs. This kit enables efficient isolation and purification of target T cells from peripheral blood samples, yielding high‑purity cell material to ensure the quality of downstream experiments and downstream applications.
- T-cell activation magnetic beads
The “initiator” of activation and proliferation signals, mimicking antigen-presenting cells through surface anti‑CD3/CD28 antibodies, delivers activating signals that trigger the critical transition of T cells from a quiescent state to activation and proliferation.
- HiXpan ® Cell culture supplement (platelet lysate)
Cell culture supplements provide activated T cells with a variety of growth factors and nutrients, facilitating cell expansion and maintaining cellular physiological activity.
- Cell Feeder Bottom-Permeable Cell Culture Flask
A “bioreactor” for cell expansion and maintenance, providing a long-term, stable in vitro culture environment for activated T cells.
- HiXpan ® Serum-free cell cryopreservation solution
A specialized reagent for cryopreservation of cells, designed to maximize the preservation of cellular structure and physiological function, maintain stable cell viability during freezing, and ensure high post-thaw survival rates and intact biological characteristics.
To support your cutting-edge research, we have launched a dedicated technical express service. Led by senior engineer Xu Yuandong, we offer end-to-end support across the entire lifecycle, from consultation to the delivery of tangible results:
- One-on-one expert consultation: We tailor the optimal solution to your specific experimental roadmap and technical challenges.
- Frontier Knowledge Base Sharing: Gain early access to the latest technical white papers, application case studies, and operational guides, keeping you one step ahead.
- End-to-end support and guidance: From precise product selection and standardized operational instructions to in-depth data analysis, we ensure a seamless experimental workflow.
- Contact us now: Mobile: 17369407396 | Email: xuyuandong@hys-bio.com
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board